SG11201610699XA - Manufacture and cryopreservation of fucosylated cells for therapeutic use - Google Patents

Manufacture and cryopreservation of fucosylated cells for therapeutic use

Info

Publication number
SG11201610699XA
SG11201610699XA SG11201610699XA SG11201610699XA SG11201610699XA SG 11201610699X A SG11201610699X A SG 11201610699XA SG 11201610699X A SG11201610699X A SG 11201610699XA SG 11201610699X A SG11201610699X A SG 11201610699XA SG 11201610699X A SG11201610699X A SG 11201610699XA
Authority
SG
Singapore
Prior art keywords
cryopreservation
manufacture
therapeutic use
fucosylated cells
fucosylated
Prior art date
Application number
SG11201610699XA
Other languages
English (en)
Inventor
Stephen D Wolfe
Original Assignee
Targazyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targazyme Inc filed Critical Targazyme Inc
Publication of SG11201610699XA publication Critical patent/SG11201610699XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0006—Modification of the membrane of cells, e.g. cell decoration
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/16—Physical preservation processes
    • A01N1/162—Temperature processes, e.g. following predefined temperature changes over time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01065—3-Galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase (2.4.1.65), i.e. alpha-1-3 fucosyltransferase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/724—Glycosyltransferases (EC 2.4.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Materials For Medical Uses (AREA)
SG11201610699XA 2014-07-07 2015-07-07 Manufacture and cryopreservation of fucosylated cells for therapeutic use SG11201610699XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462021328P 2014-07-07 2014-07-07
PCT/US2015/039370 WO2016007506A1 (en) 2014-07-07 2015-07-07 Manufacture and cryopreservation of fucosylated cells for therapeutic use

Publications (1)

Publication Number Publication Date
SG11201610699XA true SG11201610699XA (en) 2017-01-27

Family

ID=55064767

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201610699XA SG11201610699XA (en) 2014-07-07 2015-07-07 Manufacture and cryopreservation of fucosylated cells for therapeutic use

Country Status (9)

Country Link
US (3) US20170121673A1 (https=)
EP (1) EP3167046A4 (https=)
JP (3) JP2017525340A (https=)
KR (1) KR102505009B1 (https=)
CN (2) CN106687581A (https=)
AU (2) AU2015288052B2 (https=)
CA (1) CA2954534C (https=)
SG (1) SG11201610699XA (https=)
WO (1) WO2016007506A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7332334B2 (en) 2003-04-18 2008-02-19 Oklahoma Medical Research Foundation Hematopoietic stem cells treated by in vitro fucosylation and methods of use
US20140161782A1 (en) 2008-06-09 2014-06-12 Targazyme, Inc. Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucoslytransferase
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
JP6493692B2 (ja) 2013-03-15 2019-04-10 セルジーン コーポレイション 修飾されたｔリンパ球
CA2954534C (en) * 2014-07-07 2023-04-04 Targazyme, Inc. Manufacture and cryopreservation of fucosylated cells for therapeutic use
SG11201705401YA (en) * 2014-12-30 2017-08-30 The Brigham And Women`S Hospital Inc Methods to improve cell therapy
IL309689B1 (en) * 2017-02-28 2026-02-01 Univ Central Florida Res Found Inc PM21 particles to enhance NK cell migration to the bone marrow
CN108617638B (zh) * 2017-03-22 2020-01-24 拜西欧斯（北京）生物技术有限公司 组织和/或细胞冻存保护液及其制备与应用
CN108925548A (zh) * 2017-05-24 2018-12-04 西比曼生物科技（香港）有限公司 一种冻存细胞制剂及细胞复苏方式
CN107012119B (zh) * 2017-05-31 2020-03-17 东莞市保莱生物科技有限公司 一种从骨髓中提取免疫细胞的方法
IL276365B2 (en) 2018-02-01 2023-10-01 Nkmax Co Ltd A method for the production of natural killer cells and a preparation for cancer treatment
CN108404219B (zh) * 2018-02-11 2020-09-29 华中科技大学 一种基于冷冻铸造技术的小口径人工血管及其制备方法
CN112135901A (zh) * 2018-03-01 2020-12-25 格雷戈里奥马拉尼翁医院生物医学研究基金会 获得源自胸腺组织的调节性t细胞的方法及所述细胞作为细胞免疫疗法在免疫系统失调中的用途
WO2019226618A1 (en) * 2018-05-22 2019-11-28 Nantkwest, Inc. Methods and systems for cell bed formation during bioprocessing
JP7072147B2 (ja) * 2018-09-13 2022-05-20 極東製薬工業株式会社 間葉系幹細胞の凍害保護液とその利用
CN114615886A (zh) * 2019-08-29 2022-06-10 得克萨斯大学体系董事会 细胞冷冻保存培养基
CN114929249A (zh) * 2019-11-29 2022-08-19 Nkmax有限公司 产生自然杀伤细胞及其组合物的方法
US12188049B2 (en) 2020-04-14 2025-01-07 Tzu Chi University Methods for mobilizing stem cells
CN112913832A (zh) * 2021-01-27 2021-06-08 河南省华隆生物技术有限公司 一种滋养层细胞的保存方法
EP4316498A4 (en) 2021-03-30 2025-03-26 Kaneka Corporation Trypsin inhibition method, and method for producing cell preparation in which same is used
JP2022159210A (ja) * 2021-03-31 2022-10-17 株式会社カネカ 凍結接着性幹細胞の製造方法
CN113151163A (zh) * 2021-04-23 2021-07-23 优牙生物科技(上海)有限公司 一种使用牙髓干细胞制剂修复子宫内膜损伤的方法
CN113396894A (zh) * 2021-07-06 2021-09-17 南方医科大学南方医院 适用于单位毛囊保存的复合冻存液及其制备方法和应用
CN116649328A (zh) * 2023-05-10 2023-08-29 杭州中赢生物医疗科技有限公司 一种人类活性免疫细胞冻存液及其冻存方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789147A (en) 1994-12-05 1998-08-04 New York Blood Center, Inc. Method for concentrating white cells from whole blood by adding a red cell sedimentation reagent to whole anticoagulated blood
AU2730497A (en) * 1996-04-17 1997-11-07 Case Western Reserve University Cryopreservation and extensive subculturing of human mesenchymal stem cells
AU8005098A (en) 1997-06-06 1998-12-21 Governors Of The University Of Alberta, The Alpha1,3-fucosyltransferase of helicobacter pylori
US6461835B1 (en) 1998-09-03 2002-10-08 The University Of Oklahoma Fucosyltransferases, polynucleotides encoding fucosyltransferases, and transgenic mammal incorporating same
US20060210558A1 (en) 2000-10-18 2006-09-21 Robert Sackstein Hematopoietic cell selectin ligand polypeptides and methods of use thereof
CA2431901A1 (en) * 2000-12-14 2002-06-20 The University Of British Columbia Crystal structures of retaining glycosyltransferases
CA2474968A1 (en) * 2002-01-31 2003-08-07 Asahi Techno Glass Corporation Cryopreservation medium for primate embryo stem cells and cryopreservation method
US7332334B2 (en) * 2003-04-18 2008-02-19 Oklahoma Medical Research Foundation Hematopoietic stem cells treated by in vitro fucosylation and methods of use
WO2005017115A2 (en) * 2003-08-11 2005-02-24 Mount Sinai School Of Medicine Of New York University Cord blood-derived hematopoietic progenitor cells
US20100143969A1 (en) * 2005-03-24 2010-06-10 Neose Technologies, Inc. Expression of soluble, active eukaryotic glycosyltransferases in prokaryotic organisms
JP2008539796A (ja) * 2005-05-20 2008-11-20 バイレクシス コーポレイション 初代細胞の形質導入
US8198045B2 (en) * 2006-04-19 2012-06-12 Biogenerix Ag Expression of O-glycosylated therapeutic proteins in prokaryotic microorganisms
EP3336174A1 (en) * 2006-06-02 2018-06-20 Robert Sackstein Compositions and methods for modifying cell surface glycans
WO2009020201A1 (ja) * 2007-08-08 2009-02-12 Kyowa Hakko Kirin Co., Ltd. 単離された細胞集団
ES2627043T3 (es) * 2008-06-09 2017-07-26 Targazyme, Inc. Aumento de la eficacia de la terapia celular incluyendo tratamiento con alfa 1-3 fucoslitransferasa
JP5615509B2 (ja) * 2009-03-31 2014-10-29 北海道公立大学法人 札幌医科大学 フコシル化糖鎖産生細胞用物質送達担体
US8409838B2 (en) * 2009-06-02 2013-04-02 Regeneron Pharmaceuticals, Inc. Fucosylation-deficient cells
US20100311036A1 (en) * 2009-06-09 2010-12-09 University Of South Carolina Methods for Augmentation of Cell Cryopreservation
EP2480671B8 (en) * 2009-09-22 2015-10-28 ProBioGen AG Process for producing molecules containing specialized glycan structures
EP2507627A2 (en) * 2009-12-04 2012-10-10 Momenta Pharmaceuticals, Inc. Antennary fucosylation in glycoproteins from cho cells
CN102648708B (zh) * 2011-02-25 2014-08-13 深圳华大方舟生物技术有限公司 一种用于胚胎或细胞的冷冻液及其用途
CA2954534C (en) * 2014-07-07 2023-04-04 Targazyme, Inc. Manufacture and cryopreservation of fucosylated cells for therapeutic use

Also Published As

Publication number Publication date
KR20170041204A (ko) 2017-04-14
CN114540266A (zh) 2022-05-27
JP7788486B2 (ja) 2025-12-18
EP3167046A4 (en) 2017-12-20
AU2015288052B2 (en) 2021-12-16
JP2017525340A (ja) 2017-09-07
US20230014609A1 (en) 2023-01-19
KR102505009B1 (ko) 2023-03-03
AU2015288052A1 (en) 2017-02-02
CN106687581A (zh) 2017-05-17
CA2954534A1 (en) 2016-01-14
JP2024099565A (ja) 2024-07-25
US20190062694A1 (en) 2019-02-28
AU2022201639A1 (en) 2022-03-31
WO2016007506A1 (en) 2016-01-14
CA2954534C (en) 2023-04-04
EP3167046A1 (en) 2017-05-17
US20170121673A1 (en) 2017-05-04
JP2022065029A (ja) 2022-04-26

Similar Documents

Publication Publication Date Title
SG11201610699XA (en) Manufacture and cryopreservation of fucosylated cells for therapeutic use
IL250415B (en) Antibodies against pd-l and methods of using them
GB201403093D0 (en) Therapeutic compounds and their use
ZA201705060B (en) Use of picolinamides as fungicides
ZA201703779B (en) Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
GB201418350D0 (en) Dispenser and methods of use thereof
ZA201605639B (en) Hppd variants and methods of use
IL247072A0 (en) Medical use
IL313511A (en) Compounds acting on glycans and methods of using them
IL251246A0 (en) Therapeutically active compounds and methods of use
PL3089971T3 (pl) Związki i sposoby ich zastosowania
SG11201609254YA (en) Therapeutic placental compositions, methods of making and methods of use
ZA201606243B (en) Hppd variants and methods of use
IL283335B (en) Dihydropyrimidine-2-one compounds and their medical use
IL247325A0 (en) Therapeutic methods using noribogaine and related compounds
SG11201605915WA (en) Furo-3-carboxamide derivatives and methods of use
IL258192A (en) Medicinal compounds and methods of using them
ZA201606450B (en) Compounds and their methods of use
PL3129398T3 (pl) Nowe środki medyczne i ich zastosowanie
ZA201607466B (en) Therapeutic use of grape seed products
IL254732A0 (en) In vitro preservation of therapeutic cells
GB201403697D0 (en) Compounds and methods of use
TWM488971U (en) Structure of surgical knife
HK1238286A1 (en) Manufacture and cryopreservation of fucosylated cells for therapeutic use
TWM489058U (en) Structure of medical tweezers